Bevacizumab (anti-VEGF)

Product Name：Bevacizumab biosimilar

CAS No.:    216974-75-3                           

Formula:   C₆₆₃₈H₁₀₁₆₀N₁₇₂₀O₂₁₀₈S₄₄                          

Molecular Weight：  149 kDa                  

Type:   Whole antibody                      

Target：VEGF-A
Antibody Form: Purified immunoglobulin
Physical Form:  Solution in phosphate buffered saline
Storage:  -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.

Description
Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab  biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab biosimilar has an approximate molecular weight of 149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium. 

Biological Activity
Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments

For research use only.Not for use in humans